ENOV

+ Watchlist + Portfolio

Enovis Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $26.50
52-Week Range: $19.14 – $34.28
Market Cap: $1.51B
P/E (TTM): —
EPS (TTM): -19.04
Dividend Yield: —

Advanced Metrics

Price/Book: 1.02
PEG Ratio: 3.45
Return on Equity: -54.14%
Return on Assets: 1.19%
Gross Margin: 61.32%
Operating Margin: 4.18%
Profit Margin: -47.97%
Current Ratio: 1.99
Debt/Equity: 0.93
Total Debt: $1.37B
Free Cash Flow: $185.57M
Revenue Growth: 3.20%
Earnings Growth: —
Enterprise Value: $2.87B

ENOV Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.56B	$1.71B	$2.11B	$2.25B
Cost of Revenue	$693.72M	$716.42M	$926.87M	$902.79M
Gross Profit	$869.38M	$990.78M	$1.18B	$1.35B
Research & Development	$60.83M	$75.33M	$91.30M	$120.33M
Selling, General & Admin	$772.91M	$830.30M	$1.03B	$1.07B
Operating Expenses	$960.04M	$1.04B	$1.28B	$1.36B
Operating Income	-$90.66M	-$48.37M	-$103.43M	-$18.87M
EBITDA	$241.69M	$169.73M	-$481.03M	-$830.22M
Pretax Income	-$2.07M	-$67.13M	-$822.92M	-$1.16B
Income Tax	$36.12M	-$13.29M	$4.49M	$22.29M
Net Income	-$13.29M	-$33.26M	-$825.49M	-$1.18B
Diluted EPS	-0.25	-0.61	-14.93	-20.75
Diluted Shares	53.17M	54.98M	55.29M	57.08M

ENOV Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$24.30M	$36.19M	$48.17M	$36.39M
Receivables	$267.38M	$291.48M	$407.03M	$442.79M
Inventory	$426.64M	$468.83M	$547.12M	$584.38M
Current Assets	$795.02M	$896.52M	$1.15B	$1.21B
Total Assets	$4.27B	$4.51B	$4.72B	$3.83B
Current Liabilities	$565.20M	$369.61M	$529.00M	$598.47M
Long-Term Debt	$40.00M	$466.16M	$1.31B	$1.26B
Total Debt	$334.82M	$536.42M	$1.40B	$1.38B
Total Liabilities	$823.45M	$1.09B	$2.15B	$2.34B
Retained Earnings	$575.73M	$542.47M	-$283.02M	-$1.47B
Shareholders' Equity	$3.45B	$3.42B	$2.56B	$1.49B
Working Capital	$229.82M	$526.91M	$617.45M	$608.59M
Net Debt	$234.98M	$429.97M	$1.28B	$1.26B

ENOV Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$55.86M	$134.99M	$113.50M	$217.29M
Capital Expenditure	-$105.45M	-$122.22M	-$180.71M	-$197.38M
Free Cash Flow	-$161.31M	$12.77M	-$67.21M	$19.92M
Depreciation & Amortisation	$219.71M	$217.11M	$284.80M	$294.38M
Stock-Based Compensation	$38.95M	$34.06M	$29.66M	$32.92M
Investing Cash Flow	-$176.39M	-$242.47M	-$955.47M	-$179.37M
Financing Cash Flow	-$465.13M	$127.80M	$846.82M	-$52.40M
Net Change in Cash	-$697.38M	$20.32M	$4.85M	-$14.48M

ENOV Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$558.83M	$564.54M	$548.91M	$575.76M	$589.15M
Cost of Revenue	$226.60M	$229.85M	$220.00M	$226.34M	$223.67M
Gross Profit	$332.23M	$334.70M	$328.91M	$349.42M	$365.49M
Research & Development	$28.53M	$30.70M	$29.74M	$31.36M	$31.53M
Selling, General & Admin	$269.02M	$267.07M	$263.62M	$270.44M	$282.81M
Operating Expenses	$375.14M	$350.78M	$337.05M	$301.17M	$356.25M
Operating Income	-$42.91M	-$16.08M	-$8.14M	$48.25M	$9.24M
EBITDA	$23.27M	$55.19M	-$483.66M	-$425.02M	$83.16M
Pretax Income	-$57.35M	-$25.65M	-$566.87M	-$509.55M	$634.00K
Income Tax	-$1.77M	$10.80M	$4.00M	$9.26M	$9.04M
Net Income	-$55.97M	-$36.74M	-$571.15M	-$520.59M	-$8.76M
Diluted EPS	-0.98	-0.64	-9.99	-9.10	-0.15
Diluted Shares	57.11M	57.40M	57.17M	57.21M	58.43M

ENOV Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$38.46M	$44.07M	$33.62M	$36.39M	$33.13M
Receivables	$435.62M	$453.70M	$431.77M	$442.79M	$444.21M
Inventory	$585.91M	$628.22M	$613.75M	$584.38M	$602.54M
Current Assets	$1.22B	$1.28B	$1.28B	$1.21B	$1.24B
Total Assets	$4.88B	$5.02B	$4.43B	$3.83B	$3.83B
Current Liabilities	$477.42M	$568.18M	$575.44M	$598.47M	$608.66M
Long-Term Debt	$1.37B	$1.37B	$1.34B	$1.26B	$1.29B
Total Debt	$1.46B	$1.46B	$1.44B	$1.38B	$1.41B
Total Liabilities	$2.25B	$2.44B	$2.41B	$2.34B	$2.35B
Retained Earnings	-$338.99M	-$375.73M	-$946.87M	-$1.47B	-$1.48B
Shareholders' Equity	$2.62B	$2.58B	$2.02B	$1.49B	$1.48B
Working Capital	$740.76M	$712.17M	$704.68M	$608.59M	$631.02M
Net Debt	$1.35B	$1.35B	$1.33B	$1.26B	$1.29B

ENOV Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.60M	$47.77M	$82.58M	$88.54M	$23.95M
Capital Expenditure	-$43.26M	-$44.37M	-$53.49M	-$56.25M	-$52.80M
Free Cash Flow	-$44.86M	$3.40M	$29.09M	$32.29M	-$28.85M
Depreciation & Amortisation	$71.44M	$71.55M	$74.38M	$77.01M	$73.36M
Stock-Based Compensation	$7.41M	$8.67M	$8.73M	$8.11M	$8.75M
Investing Cash Flow	-$60.52M	-$49.80M	-$56.06M	-$12.99M	-$53.09M
Financing Cash Flow	$51.19M	$6.23M	-$36.91M	-$72.92M	$26.02M
Net Change in Cash	-$10.92M	$4.20M	-$10.39M	$2.64M	-$3.12M

Market Snapshot

About

Enovis Corp. is a medical technology company focused on developing and manufacturing orthopedic and rehabilitation products. The company operates through two segments: Prevention & Recovery, which provides orthopedic soft goods and physical therapy products, and Reconstructive, which offers surgical implants and instruments. Enovis serves healthcare providers, patients, and consumers globally with brands including DonJoy, Chattanooga, and DePuy Synthes reconstructive products. The company was formed through the 2022 separation from Colfax Corporation.